Sustained Top-Line Growth
Fiscal 2026 net sales grew 25% year-over-year; Q4 net sales grew 35% YoY. Company reported its 29th consecutive quarter of net sales growth and 7th consecutive year of industry-leading results.
Strong Portfolio Performance and Market Share Gains
e.l.f. Cosmetics delivered approximately $1.8 billion in global retail sales and increased U.S. market share by 115 basis points in fiscal 2026 (largest share gain among ~1,000 Nielsen-tracked cosmetics brands). e.l.f. has grown share +29 bps over 7 years and holds 13% national share in mass color cosmetics (21% at Target).
Acquisitions Driving Diversification and Growth
Rhode delivered over $500 million in global retail sales on an annualized basis and approximately $390 million in net sales (growing net sales >80% YoY). Naturium delivered nearly $250 million in global retail sales (double pre-acquisition levels); non-e.l.f. brands rose from 0% to ~30% of global consumption over 3 years.
Skincare Momentum
Skin care mix increased from 9% to 23% of global consumption; e.l.f. SKIN reached ~ $200 million in global retail sales and moved from #25 to #11 in U.S. mask care ranking over 5 years; Rhode and Naturium are among the fastest growing skincare brands.
Profitability and Margins (FY26)
Adjusted EBITDA grew 13% in fiscal 2026 with 20% adjusted EBITDA margins for the year. Q4 gross margin was 73%, up ~140 basis points YoY.
Strong International Expansion
International net sales grew 38% in fiscal 2026 and 75% in Q4; company launched with 8 international retail customers across 14 countries in FY26 and plans Sephora Europe rollout for Rhode across 19 countries (Sept launch).
Improved Supply Chain and Manufacturing Diversification
Manufacturing outside China increased from ~1% to over 45% of production over the past 3 years, reducing geographic concentration risk.
Healthy Balance Sheet & Capital Actions
Ended fiscal year with $290 million cash (up from $149 million prior year), repurchased ~$50 million of stock during the year, and maintained net debt <2x adjusted EBITDA with ~ $400 million remaining under a $500 million repurchase authorization.